英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

alliterative    音标拼音: [əl'ɪtɚətɪv] [əl'ɪtɚ,etɪv]
a. 头韵的,头韵体的

头韵的,头韵体的

alliterative
adj 1: having the same consonant at the beginning of each
stressed syllable; "alliterative verse"

Alliterative \Al*lit"er*a*tive\ (?; 277), a.
Pertaining to, or characterized by, alliteration; as,
alliterative poetry. -- {Al*lit"er*a*tive*ly}, adv. --
{Al*lit"er*a*tive*ness}, n.
[1913 Webster]


请选择你想看的字典辞典：
单词字典翻译
Alliterative查看　Alliterative　在百度字典中的解释百度英翻中〔查看〕
Alliterative查看　Alliterative　在Google字典中的解释Google英翻中〔查看〕
Alliterative查看　Alliterative　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Metastatic castration-resistant prostate cancer (mCRPC)
    Overview Metastatic castration-resistant prostate cancer (mCRPC) is prostate cancer that has spread away from the prostate and no longer responds to hormone therapy treatments Hormone therapy for prostate cancer, also called androgen deprivation therapy (ADT), lowers the levels of the hormone testosterone in the body Prostate cancer cells typically use testosterone to help them grow
  • Metastatic Castration-Sensitive Prostate Cancer: Optimizing . . .
    Prostate cancer accounts for one in every five cancer diagnoses, making it the most common cancer in men, and metastatic prostate cancer is the second most common cause of cancer-related deaths in men in the United States 1 The incidence of prostate cancer began to decline in 2000, and it has more rapidly declined since the U S Preventive
  • Overview of systemic treatment for recurrent or metastatic . . .
    The options for initial systemic therapy for advanced, recurrent, and metastatic CSPC are discussed elsewhere; there are also separate discussion of the diagnostic evaluation, local salvage treatments, and the role of systemic therapy for males with a rising serum PSA after definitive local therapy
  • Metastatic Prostate Cancer: Androgen deprivation therapy
    Castration-sensitive prostate carcinoma (CSPC): CSPC is an advanced prostate carcinoma (biochemical progression or proven metastases) with a response to androgen deprivation (see below) Depending on the detection of metastases on imaging, the stage is referred to as M0 CSPC or M1 CSPC It isn't easy to distinguish stage M0 CSPC from a local recurrence after curative therapy Histology and PSA
  • Frontiers | Targeted and immunotherapeutic strategies for . . .
    The disease can be categorized based on its response to ADT: Castration-Sensitive Prostate Cancer (CSPC) and Castration-Resistant Prostate Cancer (CRPC) CSPC is an early stage of metastatic prostate cancer, in which ADT, as an important treatment method for cancer, can effectively inhibit tumor growth by reducing testosterone levels in the body
  • ADVANCED PROSTATE CANCER
    Metastatic: Cancer has spread to other parts of the body, such as the bones, lymph nodes, lungs, or liver This is also referred to as Stage IV prostate cancer Castration-Sensitive Prostate Cancer (CSPC, also called Hormone-Sensitive Prostate Cancer): A form of prostate cancer that still responds to testosterone suppression therapy
  • Advanced Prostate Cancer: AUA SUO Guideline (2026)
    The management of advanced prostate cancer is rapidly evolving To assist in clinical decision-making, evidence-based guideline statements were developed to provide a rational basis for evidence-based treatment This guideline covers advanced prostate cancer, including disease stages that range from prostate-specific antigen (PSA) recurrence after exhaustion of local treatment options to
  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Metastasis-directed therapy and standard of care versus . . .
    We used a structured data collection form to collect individual patient data from eligible studies, including PSA at enrolment, outcomes, age, baseline staging imaging used, number of metastases, baseline castration-resistant prostate cancer (CRPC) versus castration-sensitive prostate cancer (CSPC), and organ systems involved (appendix p 14)





中文字典-英文字典  2005-2009